Latest Ratios: P/E Ratio 0.6x · EV/EBITDA -1.2x · ROE 22.2%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $30M | $21M | $23M | — | — |
| Enterprise Value | $-82572970 | $-90961282 | $-89645653 | — | — |
| P/E Ratio → | 0.57 | 0.41 | 0.50 | — | — |
| P/S Ratio | 0.17 | 0.12 | 0.11 | — | — |
| P/B Ratio | 0.11 | 0.08 | 0.12 | — | — |
| P/FCF | 0.81 | 0.58 | 0.45 | — | — |
| P/OCF | 0.76 | 0.54 | 0.42 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | -0.52 | -0.44 | — | — |
| EV / EBITDA | -1.18 | -1.30 | -1.21 | — | — |
| EV / EBIT | -1.22 | -1.11 | -1.22 | — | — |
| EV / FCF | — | -2.49 | -1.73 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | 73.3% | 73.3% | 76.0% | 70.9% | 65.9% |
| Operating Margin | 38.9% | 38.9% | 34.2% | 36.5% | 11.6% |
| Net Profit Margin | 29.4% | 29.4% | 22.7% | 20.3% | 3.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | 22.2% | 22.2% | 27.5% | 31.3% | 5.9% |
| ROA | 15.8% | 15.8% | 17.8% | 16.3% | 2.8% |
| ROIC | 43.4% | 43.4% | 72.3% | 78.0% | 20.9% |
| ROCE | 25.7% | 25.7% | 37.9% | 48.6% | 16.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.06 | 0.16 | 0.15 |
| Debt / EBITDA | 0.74 | 0.74 | 0.16 | 0.28 | 0.62 |
| Net Debt / Equity | — | -0.43 | -0.58 | -0.56 | -0.33 |
| Net Debt / EBITDA | -1.60 | -1.60 | -1.52 | -0.97 | -1.37 |
| Debt / FCF | — | -3.07 | -2.17 | -2.03 | — |
| Interest Coverage | 512.05 | 512.05 | 2596.61 | 1625.56 | 754.05 |
Net cash position: cash ($164M) exceeds total debt ($52M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 3.78 | 3.78 | 3.01 | 1.79 | 1.12 |
| Quick Ratio | 3.74 | 3.74 | 2.99 | 1.76 | 1.10 |
| Cash Ratio | 2.68 | 2.68 | 2.04 | 1.11 | 0.53 |
| Asset Turnover | — | 0.46 | 0.77 | 0.75 | 0.77 |
| Inventory Turnover | 16.59 | 16.59 | 33.02 | 18.19 | 43.94 |
| Days Sales Outstanding | — | 110.62 | 85.63 | 100.20 | 91.47 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 243.2% | 199.9% | — | — |
| FCF Yield | 100.0% | 172.6% | 224.0% | — | — |
| Buyback Yield | 16.9% | 23.6% | 0.0% | — | — |
| Total Shareholder Yield | 16.9% | 23.6% | 0.0% | — | — |
| Shares Outstanding | — | $103M | $97M | $94M | $15M |
Geographic and Regulatory Concentration
Based on reported figures, SBCWW trades at a P/S ratio of 0.19 and a P/B of 0.12, suggesting that the market is heavily discounting the company's future earnings potential relative to its book value and historical performance in the Japanese aesthetic medical services sector.
The current valuation multiples appear to reflect significant investor caution regarding the sustainability of the company's management-fee model amidst a period of revenue contraction. Investors should monitor whether this deep discount represents a mispricing of the firm's platform-based moat or a rational reaction to the lack of clear forward-looking guidance.
According to recent financial statements, the company's ROIC has fluctuated significantly, dropping from a peak of 165.8% in 2024Q2 to 9.7% in 2026Q1, which indicates that the firm's ability to compound returns on invested capital is currently under pressure from declining operational efficiency.
The sharp decline in ROIC suggests that the company's capital allocation strategy may be struggling to maintain its historical effectiveness as the core Japanese market matures. This trend warrants further investigation to determine if the capital base is being bloated by unproductive cash reserves or if the underlying business model is becoming more capital-intensive.
As reported in quarterly filings, the cash conversion cycle has swung from -74 days in 2023Q4 to 74 days in 2025Q4, highlighting significant instability in the company's ability to manage its working capital and collect payments from its franchisee network efficiently.
The volatility in DSO and DPO suggests that the company's leverage over its suppliers and franchisees may be shifting, potentially impacting the firm's liquidity position. Investors should interpret these swings as a sign of operational friction that may be masking the true underlying cash-generating capability of the management platform.
Based on the company's latest balance sheet, the current ratio of 3.82 in 2026Q1 demonstrates a strong liquidity position, providing a substantial cushion against the ongoing revenue contraction and potential volatility in the Japanese aesthetic medical market that the firm currently navigates.
This robust liquidity profile appears to be driven by a significant cash pile, which serves as a defensive mechanism against the firm's current operational challenges. While this provides safety, it also raises questions about the lack of strategic reinvestment opportunities available to management to reverse the current top-line decline.
The P/E ratio is frequently misapplied to SBCWW, as it fails to account for the company's unique role as a platform provider rather than a traditional medical service operator, thereby obscuring the true earnings quality derived from recurring management fees versus one-time equipment sales.
Investors should instead focus on EV/EBITDA or adjusted free cash flow metrics to better capture the firm's operational leverage and cash-generating capacity. Relying on P/E in this context may lead to an inaccurate assessment of the company's value, as it ignores the significant impact of non-recurring items and the firm's specific capital structure.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SBCWW stock.
SBC Medical Group Holdings Incorporated's current P/E ratio is 0.6x. The historical average is 0.5x. This places it at the 100th percentile of its historical range.
SBC Medical Group Holdings Incorporated's current EV/EBITDA is -1.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
SBC Medical Group Holdings Incorporated's return on equity (ROE) is 22.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 21.7%.
Based on historical data, SBC Medical Group Holdings Incorporated is trading at a P/E of 0.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
SBC Medical Group Holdings Incorporated has 73.3% gross margin and 38.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
SBC Medical Group Holdings Incorporated's Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.